+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 19Years - 69Years
All Genders
ID07917338

Evaluating Oral N-Acetylcysteine Treatment for Diabetic Macular Edema in Adults with Type 2 Diabetes

Led by Khadija Ahmed Mhrose Glal · Updated on 2026-11-04

50

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Diabetic macular edema DME is a serious complication of diabetic retinopathy that can cause vision loss among adults with type 2 diabetes. This research evaluates the effects of oral N-acetylcysteine NAC, an antioxidant compound, on DME. The study aims to understand if NAC can reduce retinal swelling caused by blood vessel leakage, which results from oxidative stress and vascular issues in diabetic eyes. Participants will be randomly assigned to receive either oral NAC at 1200 mg daily 600 mg twice a day or no intervention. The treatment period lasts for three months, during which researchers will monitor changes in retinal thickness using imaging scans and measure blood markers linked to oxidative damage and vascular stability. The study does not use placebo or blinding. During the trial, participants will undergo eye exams including spectral-domain optical coherence tomography SD-OCT to measure retinal thickness and tests for visual acuity. Blood samples will be taken to assess levels of malondialdehyde MDA and angiopoietin-2 Ang-2. Researchers will also record any need for rescue therapies or adverse events. The total participation time is three months, focusing on safety and treatment effects.

CONDITIONS

Brief Title

Oral N-Acetylcysteine on Diabetic Macular Edema

Research Team

E

Esraa Farag

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here